Test

TKTKTKTKTKTK

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Pharmaceutical Executive Daily: Hanmi Licenses HM17321 to Genentech

ByNicholas Jacobus

August 24th 2026

Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321

ByNicholas Jacobus

August 24th 2026

Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline

ByIvo Carre

August 24th 2026

Focusing on Asset Acquisition Over Building a Single Platform Technology

ByMike Hollan,Ying Huang, PhD

August 24th 2026

What the Peptide Advisory Vote Actually Means: Q&A with James LaValle

ByNicholas Jacobus,James LaValle

August 24th 2026

Test

Related Content

Pharmaceutical Executive Daily: Hanmi Licenses HM17321 to Genentech

Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321

Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline

Focusing on Asset Acquisition Over Building a Single Platform Technology

What the Peptide Advisory Vote Actually Means: Q&A with James LaValle

Trending on PharmExec

Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline

What the Peptide Advisory Vote Actually Means: Q&A with James LaValle

Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321

Focusing on Asset Acquisition Over Building a Single Platform Technology

Pharmaceutical Executive Daily: Hanmi Licenses HM17321 to Genentech